Back to News
Market Impact: 0.3
Vanda Pharmaceuticals Inc. Reports Third Quarter 2026 Financial Results
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Vanda Pharmaceuticals reported Q3 2026 net product sales of $69.8 million, up 24% from $56.3 million in Q3 2025. The excerpt provides no further earnings results or outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
VNDA0.70
More News
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Alphabet just had its worst day as a public company. BofA now values Google search at a lower multiple than fossil fuel stocks
- Alphabet’s stock has worst day in over 20 years, dragging the S&P 500 to first loss in four days
- Warren urges DOJ criminal probe of Bank of America over anti-money-laundering violations
- Taiwan Stocks Heads for Correction as Global AI Selloff Deepens